BioCentury | Mar 20, 2018
Distillery Therapeutics

Infectious disease

...affiliation as above email: ali.amara@inserm.fr Hongjiang Li Institut National de la Sante et de la Recherche Medicale (INSERM) G protein beta polypeptide 2-like...
BioCentury | Jul 10, 2017
Distillery Therapeutics

Cancer

...2017 doi:10.1038/ncomms15884 CONTACT: Claire M. Dubois, Université de Sherbrooke, Sherbrooke, Quebec email: claire.dubois@usherbrooke.ca Claire Quang Universite de Sherbrooke G protein beta polypeptide 2-like...
BioCentury | Jun 21, 2012
Distillery Therapeutics

Indication: Cancer

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Liver cancer G protein beta polypeptide 2-like 1 (GNB2L1) Patient...
BioCentury | Feb 9, 2012
Distillery Therapeutics

Indication: Cancer

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Non-small cell lung cancer (NSCLC) G protein beta polypeptide 2-like...
BioCentury | May 28, 2009
Targets & Mechanisms

New angiogenesis targets

...Alzheimer's disease (AD) FZD6 Frizzled homolog 6 G protein-coupled receptor for Wnt; signal transduction GNB2 G protein beta polypeptide 2 (GNB2)...
BioCentury | Sep 22, 2003
Company News

Eurofins, SNiP Biotech GmbH & Co. KG deal

SNiP Biotech granted to EUFI subsidiary Medigenomix (Munich, Germany) an exclusive license to SNPs in the sequence of the GNB3 gene, which codes for a G protein subunit. Medigenomix will use these SNPs for pharmacogenomics...
Items per page:
1 - 6 of 6